Production (Stage)
BioCryst Pharmaceuticals, Inc.
BCRX
$10.59
$0.201.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 74.37% | 60.77% | 47.61% | 39.88% | 7.81% |
| Total Depreciation and Amortization | 9.72% | 5.06% | 5.24% | 11.11% | 18.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -20.47% | -24.73% | -33.70% | -31.58% | 7.77% |
| Change in Net Operating Assets | -89.42% | -169.38% | 7.08% | -1.45% | 1.45% |
| Cash from Operations | 74.48% | 45.32% | 49.37% | 31.60% | 22.99% |
| Capital Expenditure | 53.99% | 48.15% | 53.13% | -45.41% | -102.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 686.14% | 141.53% | 130.95% | 119.53% | 103.38% |
| Cash from Investing | 1,066.29% | 140.00% | 124.50% | 117.69% | 102.22% |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | 310.55% |
| Total Debt Repaid | 99.24% | 99.29% | 98.95% | 99.19% | -- |
| Issuance of Common Stock | -10.08% | -53.25% | -66.79% | -75.01% | -58.21% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 82.30% | 78.21% | 79.56% | 79.39% | -- |
| Cash from Financing | -115.87% | -117.73% | -112.33% | -104.32% | -69.26% |
| Foreign Exchange rate Adjustments | -222.88% | -358.56% | 420.47% | 404.17% | -72.56% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 129.45% | 96.84% | 44.26% | 46.46% | 70.91% |